drugset / Trial / NCT04133259
Evaluate the Efficacy and Safety of HLX10 in Chronic Hepatitis B Patients
NaSingle-groupOpen-labelTreatment
Summary
A multiple-center, open-label, Phase II clinical trial to evaluate the safety and the efficacy of HLX10 in chronic hepatitis B patients.
Timeline
- Start
- 2019-12-31
- Primary completion
- 2022-04-30
- Completion
- 2022-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Serplulimab | Monoclonal antibody | 1 mg/kg | — |
| Background | Entecavir | Small molecule | — | — |
| Background | Tenofovir disoproxil fumarate | Small molecule | — | — |